APA (7th ed.) Citation

Kong, D., Yang, T., Geng, J., Jing, R., Zhang, Q., Wei, G., . . . Hu, Y. (2022). Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy. Journal of Zhejiang University-SCIENCE B: Biomedicine & Biotechnology, 23(10), 876-880. https://doi.org/10.1631/jzus.b2200128

Chicago Style (17th ed.) Citation

Kong, Delin, Tingting Yang, Jia Geng, Ruirui Jing, Qiqi Zhang, Guoqing Wei, He Huang, and Yongxian Hu. "Secondary Donor-derived CD19 CAR-T Therapy Is Safe and Efficacious in Acute Lymphoblastic Leukemia with Extramedullary Relapse After First Autologous CAR-T Therapy." Journal of Zhejiang University-SCIENCE B: Biomedicine & Biotechnology 23, no. 10 (2022): 876-880. https://doi.org/10.1631/jzus.b2200128.

MLA (9th ed.) Citation

Kong, Delin, et al. "Secondary Donor-derived CD19 CAR-T Therapy Is Safe and Efficacious in Acute Lymphoblastic Leukemia with Extramedullary Relapse After First Autologous CAR-T Therapy." Journal of Zhejiang University-SCIENCE B: Biomedicine & Biotechnology, vol. 23, no. 10, 2022, pp. 876-880, https://doi.org/10.1631/jzus.b2200128.